Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Will Manufacturing Issues Hobble Abatacept?

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

FDA's decision to push back the user fee date for Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) could have a ripple effect on the launch of the product

You may also be interested in...



Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date

The rheumatoid arthritis agent is expected to be available by the end of February.

Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date

The rheumatoid arthritis agent is expected to be available by the end of February.

Orencia Launch Anticipated By Bristol In Early 2006

Bristol-Myers Squibb expects to gain approval for its rheumatoid arthritis therapy Orencia "soon" and plans to launch the biologic in early 2006, CEO Peter Dolan said during the company's third quarter sales and earnings call Oct. 28
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS062990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By